Merck KGaA’s lab supplies unit sees Q3 EBITDA jump 30.7%

Reuters

FRANKFURT – Germany’s Merck KGaA said its Life Science unit, which supplies materials and gear to makers of vaccines and drugs, saw adjusted earnings jump 30.7% in the third quarter, driven by demand related to COVID-19.

Earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, for the division reached 824 million euros, the diversified group reported on Thursday.

In an unscheduled release last week, Merck raised its full-year profit forecast, citing very strong performance at its Life Science unit, and published forecast-beating group earnings for the quarter.

Related News:   New York, New Jersey Say Their Ports Can Take Additional Cargo While Baltimore Shut Down

(Reporting by Ludwig Burger)

tagreuters.com2021binary_LYNXMPEHAA08W-BASEIMAGE


You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.